Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer (Q37118956)

18 August 2017

1 reference

title

Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer (English)

1 reference

18 August 2017

J Michael Dixon

1

1 reference

18 August 2017

1 March 2008

1 reference

Expert Review of Anticancer Therapy

18 August 2017

1 reference

18 August 2017

8

1 reference

18 August 2017

3

1 reference

18 August 2017

453-463

1 reference

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

18 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Neoadjuvant endocrine therapy of breast cancer: a surgical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Neoadjuvant endocrine therapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Ki-67 expression in primary breast carcinomas and their axillary lymph node metastases: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Histopathology of breast carcinoma following neoadjuvant systemic therapy: a common association between letrozole therapy and central scarring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Portal hypertension and liver surgery following selective internal radiation therapy with 90Yttrium microspheres.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Refining the postmenopausal breast cancer treatment paradigm: the FACE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

Molecular Classification of Patients With Malignant Melanoma for New Therapeutic Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.3.453

21 January 2018

Identifiers

DOI

10.1586/14737140.8.3.453

1 reference

18 August 2017

1 reference

PubMed ID

18366292